Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic microangiopathy (TMA) that were treated by ec...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2017/3197042 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564435189760000 |
|---|---|
| author | Luca Lanfranco Melanie Joly Arnaud Del Bello Laure Esposito Noelle Cognard Peggy Perrin Bruno Moulin Nassim Kamar Sophie Caillard |
| author_facet | Luca Lanfranco Melanie Joly Arnaud Del Bello Laure Esposito Noelle Cognard Peggy Perrin Bruno Moulin Nassim Kamar Sophie Caillard |
| author_sort | Luca Lanfranco |
| collection | DOAJ |
| description | Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic microangiopathy (TMA) that were treated by eculizumab after ABOi KT. The first patient presented with features of TMA at postoperative day (POD) 13. Because of worsening biological parameters and no recovery of kidney function, despite seven sessions of immunoadsorption, a salvage therapy of eculizumab was started on POD 23. Kidney function slightly improved during the first 4 months after transplantation. Eculizumab was stopped at month 4. However, kidney function worsened progressively, leading to dialysis at month 13 after transplantation. The second patient presented with features of TMA at POD 1. In addition to immunoadsorption therapy, eculizumab was started on POD 6. Kidney function improved. Eculizumab was stopped on POD 64 and immunoadsorption sessions were stopped on POD 102. At the last follow-up (after 9 months), eGFR was at 43 mL/min/1.73 m2. Our case reports show the beneficial effect of eculizumab to treat ABMR after ABOi KT. However, it should be given early after diagnosing TMA associated with ABMR. |
| format | Article |
| id | doaj-art-de54843e0b544211b1f30d23f42c48e1 |
| institution | Kabale University |
| issn | 2090-6943 2090-6951 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Transplantation |
| spelling | doaj-art-de54843e0b544211b1f30d23f42c48e12025-02-03T01:11:00ZengWileyCase Reports in Transplantation2090-69432090-69512017-01-01201710.1155/2017/31970423197042Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney TransplantationLuca Lanfranco0Melanie Joly1Arnaud Del Bello2Laure Esposito3Noelle Cognard4Peggy Perrin5Bruno Moulin6Nassim Kamar7Sophie Caillard8Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, FranceDepartment of Nephrology and Transplantation, University Hospital of Strasbourg, Strasbourg, FranceDepartment of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, FranceDepartment of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, FranceDepartment of Nephrology and Transplantation, University Hospital of Strasbourg, Strasbourg, FranceDepartment of Nephrology and Transplantation, University Hospital of Strasbourg, Strasbourg, FranceDepartment of Nephrology and Transplantation, University Hospital of Strasbourg, Strasbourg, FranceDepartment of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, FranceDepartment of Nephrology and Transplantation, University Hospital of Strasbourg, Strasbourg, FranceThrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic microangiopathy (TMA) that were treated by eculizumab after ABOi KT. The first patient presented with features of TMA at postoperative day (POD) 13. Because of worsening biological parameters and no recovery of kidney function, despite seven sessions of immunoadsorption, a salvage therapy of eculizumab was started on POD 23. Kidney function slightly improved during the first 4 months after transplantation. Eculizumab was stopped at month 4. However, kidney function worsened progressively, leading to dialysis at month 13 after transplantation. The second patient presented with features of TMA at POD 1. In addition to immunoadsorption therapy, eculizumab was started on POD 6. Kidney function improved. Eculizumab was stopped on POD 64 and immunoadsorption sessions were stopped on POD 102. At the last follow-up (after 9 months), eGFR was at 43 mL/min/1.73 m2. Our case reports show the beneficial effect of eculizumab to treat ABMR after ABOi KT. However, it should be given early after diagnosing TMA associated with ABMR.http://dx.doi.org/10.1155/2017/3197042 |
| spellingShingle | Luca Lanfranco Melanie Joly Arnaud Del Bello Laure Esposito Noelle Cognard Peggy Perrin Bruno Moulin Nassim Kamar Sophie Caillard Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation Case Reports in Transplantation |
| title | Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation |
| title_full | Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation |
| title_fullStr | Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation |
| title_full_unstemmed | Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation |
| title_short | Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation |
| title_sort | eculizumab for thrombotic microangiopathy associated with antibody mediated rejection after abo incompatible kidney transplantation |
| url | http://dx.doi.org/10.1155/2017/3197042 |
| work_keys_str_mv | AT lucalanfranco eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation AT melaniejoly eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation AT arnauddelbello eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation AT laureesposito eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation AT noellecognard eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation AT peggyperrin eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation AT brunomoulin eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation AT nassimkamar eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation AT sophiecaillard eculizumabforthromboticmicroangiopathyassociatedwithantibodymediatedrejectionafteraboincompatiblekidneytransplantation |